抽象的
Symptom-driven low-dose inhaled corticosteroid–formoterol is safe and effective in mild asthma and has been recommended as one of the preferred treatment regimens at steps 1 and 2 in the 2019 update of the Global Initiative for Asthma. However, there are no data on patient preferences for this regimen.
参与者在实际研究中(ACTRN12616000377437),随机对照试验比较症状驱动的症状预后蛋白质与维持培养蛋白质和必要的特布尔妥甲醛,在最终研究访问中完成了关于治疗偏好,满意度,信仰和经验的调查。
306 (75%) out of 407 eligible participants completed the survey. Regimen preference was strongly associated with randomised treatment, as were preferences for and beliefs about preventer inhaler use. Combination preventer and reliever as-needed therapy was preferred by 135 (90%, 95% CI 85.2–94.8%) out of 150 who were randomised to as-needed budesonide–formoterol, and by 63 (40%, 95% CI 32.7–48.1%) out of 156 who were randomised to maintenance budesonide. By contrast, twice-daily preventer inhaler with a reliever inhaler as required was preferred by 15 (10%) out of 150 of those randomised to as-needed budesonide–formoterol and 93 (60%) out of 156 of those randomised to maintenance budesonide. Satisfaction with all study inhalers was high. Of patients randomised to as-needed budesonide–formoterol 92% (n=138) were confident using it as a reliever at the end of the study.
Although most participants preferred the regimen to which they had been randomised, this association was much stronger for those randomised to budesonide–formoterol as needed, indicating that most patients preferred as-needed corticosteroid–formoterol therapy if they had experienced it.
抽象的
In a clinical trial of patients with mild–moderate asthma comparing as-needed budesonide–formoterol with maintenance budesonide plus as-needed terbutaline, as-needed budesonide–formoterol was preferred by 90% of patients randomised to this treatmenthttp://bit.ly/37DdUzB
脚注
本文提供了补充材料www.qdcxjkg.com
This trial is registered with the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) with identifier number ACTRN12616000377437; UTN: U1111-1174-2273. Data availability: de-identified individual participant preference data collected during the PRACTICAL trial will be shared beginning 2 years after article publication with no end date. These data will be available to researchers who provide a methodologically sound proposal for the purposes of achieving specific aims outlined in that proposal. Proposals should be directed to R. Beasleyviaemail (richard.beasley@mrinz.ac.nz) and will be reviewed by the PRACTICAL study management committee. Requests to access data to undertake hypothesis-driven research will not be unreasonably withheld. To gain access, data requesters will need to sign a data access agreement and to confirm that data will only be used for the agreed purpose for which access was granted.
Conflict of interest: C. Baggott reports grants from Health Research Council of New Zealand, during the conduct of the study; personal fees for meeting attendance from AstraZeneca and Novartis, outside the submitted work.
Conflict of interest: H.K. Reddel reports grants from Health Research Council of New Zealand, during the conduct of the study; grants and personal fees for consultancy, advisory board and data monitoring committee work, and educational activities from AstraZeneca, grants, personal fees for consultancy, advisory board and data monitoring committee work, and educational activities and non-financial support (study medication) from GlaxoSmithKline, personal fees for data monitoring committee work from Merck, grants and personal fees for advisory board and data monitoring committee work, and educational activities from Novartis, personal fees for educational activities from Teva and Mundipharma, personal fees for educational activities and advisory board work from Boehringer Ingelheim, outside the submitted work; and is Chair of the GINA Scientific Committee.
Conflict of interest: J. Hardy reports grants from Health Research Council of New Zealand, during the conduct of the study; personal fees for meeting attendance from AstraZeneca, outside the submitted work.
兴趣冲突:J. Sparks在研究期间报道了新西兰卫生研究委员会的赠款。
兴趣冲突:在研究期间,新西兰卫生研究委员会的霍拉迪报告赠款。
Conflict of interest: A. Corin reports grants from Health Research Council of New Zealand, during the conduct of the study; grants and personal fees for meeting attendance from AstraZeneca, personal fees for lectures and meeting attendance from GlaxoSmithKline, grants from resTORbio, Regeneron, Esperion, Connect Biopharma and Luitpold, and is a committee member for PHARMAC, outside the submitted work.
Conflict of interest: B. Montgomery reports grants from Health Research Council of New Zealand, during the conduct of the study.
Conflict of interest: J. Reid reports grants from Health Research Council of New Zealand, during the conduct of the study.
Conflict of interest: D. Sheahan reports grants from Health Research Council of New Zealand, during the conduct of the study.
Conflict of interest: R.J Hancox reports grants from Health Research Council of New Zealand, during the conduct of the study; grants and reimbursement of travel expenses from AstraZeneca, reimbursement of travel expenses from Boehringer Ingelheim, personal fees for lectures from Menarini, outside the submitted work.
Conflict of interest: M. Weatherall reports grants from Health Research Council of New Zealand, during the conduct of the study.
利益冲突:R. Beasley在进行研究期间,新西兰卫生研究委员会的报告奖励;讲座,咨询委员会工作和Astrazeneca的咨询委员会工作和会议咨询,来自Glaxosmithkline和Genentech,咨询委员会的个人费用的授予,咨询委员会在提交的工作之外。
兴趣冲突:J. Fingleton在进行研究期间,新西兰健康研究委员会报告赠款;Astrazeneca的讲座,个人费用和非金融(旅行)支持,来自Glaxosmithkline和Genentech的赠款,讲座和非金融(旅行)支援的个人费用来自Boehringer Ingelheim,在提交的工作之外。
支持声明:该研究通过新西兰卫生研究理事会卫生研究委员会提供的卫生研究委员会,新西兰医学研究所(MRINZ)提供的计划赠款(15/573)资助。MRINZ对学习,监测和数据管理有全面责任。该资助者在设计,数据收集,数据分析或解释或稿件中没有作用。所有作者都可以完全访问数据分析报告,协助写入稿件并批准最终版本。随机药物在商业上购买。本文的资助信息已被存入Crossref Funder Registry.
- 已收到October 23, 2019.
- AcceptedJanuary 22, 2020.
- 复制right ©ERS 2020